Cubist Systematic Strategies LLC bought a new stake in Sensus Healthcare, Inc. (NASDAQ:SRTS – Free Report) in the 2nd quarter, HoldingsChannel reports. The firm bought 29,280 shares of the company’s stock, valued at approximately $156,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. Renaissance Technologies LLC grew its holdings in shares of Sensus Healthcare by 34.4% in the second quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock valued at $2,087,000 after purchasing an additional 100,294 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Sensus Healthcare by 128.0% in the second quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock valued at $888,000 after acquiring an additional 93,511 shares during the last quarter. Marshall Wace LLP grew its position in Sensus Healthcare by 152.4% in the second quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock worth $412,000 after acquiring an additional 46,732 shares during the period. Hillsdale Investment Management Inc. purchased a new position in Sensus Healthcare in the first quarter worth approximately $155,000. Finally, Acadian Asset Management LLC increased its stake in Sensus Healthcare by 578.6% during the second quarter. Acadian Asset Management LLC now owns 45,124 shares of the company’s stock worth $239,000 after acquiring an additional 38,474 shares during the last quarter. 25.30% of the stock is owned by institutional investors and hedge funds.
Sensus Healthcare Stock Down 2.0 %
SRTS opened at $6.42 on Wednesday. Sensus Healthcare, Inc. has a 52 week low of $1.79 and a 52 week high of $7.18. The business has a fifty day simple moving average of $6.22 and a 200-day simple moving average of $5.43. The firm has a market cap of $105.24 million, a P/E ratio of 22.14 and a beta of 1.05.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on SRTS. Roth Capital upgraded Sensus Healthcare to a “strong-buy” rating in a report on Friday, July 12th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Sensus Healthcare in a research note on Monday, August 12th.
Get Our Latest Research Report on SRTS
Sensus Healthcare Profile
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
See Also
- Five stocks we like better than Sensus Healthcare
- What Is WallStreetBets and What Stocks Are They Targeting?
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- AMD Gains Momentum With AI: Can It Beat Expectations?
- There Are Different Types of Stock To Invest In
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Want to see what other hedge funds are holding SRTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sensus Healthcare, Inc. (NASDAQ:SRTS – Free Report).
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.